Drug intelligence / Profile preview

CB307

Development stage: Unknown
Lead developer: Crescendo Biologics
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CB307 is a trispecific variable heavy-chain antibody fragment targeting **prostate-specific membrane antigen (PSMA)**, **CD137 (4-1BB)**, and **human serum albumin (HSA)**. It is designed to enhance T-cell activation specifically in the tumor microenvironment, reducing systemic toxicity. Developed by Crescendo Biologics, CB307 is primarily investigated for treating **PSMA-positive advanced and/or metastatic solid tumors**, including **prostate cancer**.

Other names: CD137 x PSMA HumabodyCD-137 x PSMA HumabodyCD 137 x PSMA Humabody

Targets

TNFRSF9 (CD137 extracellular domain)PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on CB307.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB307.

Explore the full profile